Back to Newsroom
Back to Newsroom

RDInvesting Provides Investors with Free In-Depth Equity Reports on BHI, BLOX, GMCR and MDVN

Friday, 31 January 2014 08:50 AM

Topic:

Research Driven Investing strives to provide investors with free daily equity research reports analyzing major market events. Take a few minutes to register with us free at www.RDInvesting.com and get exclusive access to our numerous stock reports and market updates.

Baker Hughes Incorporated (NYSE: BHI) shares declined 0.76 percent to close at $55.81 a share Wednesday. The stock traded between $55.08 and $56.03 on volume of 6.0 million shares traded. Analysts at Guggenheim have recently downgraded the company’s rating to "sell" from "neutral". Shares of Baker Hughes have gained approximately 20.0 percent in the past year.

Find out more about Baker Hughes including full access to the free equity report at:     
www.RDInvesting.com/BHI

Infoblox Inc. (NYSE: BLOX) shares declined 2.38 percent to close at $33.70 a share Wednesday. The stock traded between $32.89 and $35.13 on volume of 870,592 shares traded. Analysts at Zacks have recently upgraded the company’s rating to "neutral" from "underperform". Shares of Infoblox have gained approximately 75.0 percent in the past year.

Find out more about Infoblox including full access to the free equity report at:     
www.RDInvesting.com/BLOX

Green Mountain Coffee Roasters Inc. (NASDAQ: GMCR) shares declined 0.96 percent to close at $76.51 a share Wednesday. The stock traded between $75.75 and $77.16 on volume of 2.30 million shares traded. Analysts at Ned Davis Research have recently upgraded the company’s rating to "buy" from "neutral". Shares of Green Mountain Coffee Roasters have gained approximately 65.0 percent in the past year.

Find out more about Green Mountain Coffee Roasters including full access to the free equity report at:       
www.RDInvesting.com/GMCR

Medivation Inc. (NASDAQ: MDVN) shares gained 11.23 percent to close at $84.29 a share Wednesday. The stock traded between $82.60 and $87.46 on volume of 6.36 million shares traded. Analysts at JPMorgan currently have an "overweight" have recently raised its price target on the stock to $101.00 from $85.00. Shares of Medivation have gained approximately 30.0 percent year-to-date.

Find out more about Medivation including full access to the free equity report at:     
www.RDInvesting.com/MDVN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Research Driven Investing has no financial relationship with any company whose stock is mentioned in this release.

Contact:         
Research Driven Investing          
[email protected]

Topic:
Back to newsroom
Back to Newsroom
Share by: